Rare Tumours

  • Paz Fernández-OrtegaEmail author
  • Inma Bonilla
Part of the Principles of Specialty Nursing book series (PSN)


A total number of two million of persons in Europe are affected today by a rare tumour that makes up one quarter of all malignancies. The classification includes a very heterogeneous group of more than 200 different cancers. Although the increasing precision medicine has led to great advances in treatment and survivor rates of all cancers, because of the rarity of some tumours, patients have lot of difficulties to be diagnosed, to be treated or to follow up care in adequate manner.

The purpose of this chapter is to describe how cancer nurses should be aware of the specific knowledge needed to take care of these patients, which are their main concerns, and the specific needs along the cancer process. It is discussed how few patients have the opportunity to participate in clinical trials or to get the excellent multidisciplinary team that they need because of disparity in equity among countries or regions.

This chapter includes some resources and links of support networks for the patients and professionals.


Rare disease Uncommon tumour Cancer research 


No Conflict of Interest

About authors: Dr. Fernández–Ortega is the principal author. Inma Bonilla has contributed to some part of the manuscript. Both authors declare that there is no conflict of interest.


  1. 1.
    Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab. 2009;96(1):20–6. Scholar
  2. 2.
    Ray-Coquard I, Pujade Lauraine E, Le Cesne A, Pautier P, Vacher Lavenue MC, Trama A, et al. Improving treatment results with reference centres for rare cancers: where do we stand? Eur J Cancer. 2017;77:90–8. Scholar
  3. 3.
    European Union directives. Directive 2011/24/EU of the European Parliament and of the council on the application of patients’ rights in cross-border healthcare. Brussels; 2011 [cited 2018 Oct 1]. Available from:
  4. 4.
    Decosterd S, Murphy A. Soins en oncologie. 2016;(3):5–9. Available from:
  5. 5.
    Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. Lancet Oncol. 2017;18(8):1022–39.CrossRefGoogle Scholar
  6. 6.
    Public Health England Reports. Cancer 52 the common voice for less common cancers. Rare and less common cancers. National Cancer Registration and Analysis Service (NCRAS).
  7. 7.
    Gatta G, Trama A, Capocaccia R; RARECARENet Working Group. Epidemiology of rare cancers and inequalities in oncologic outcomes. Eur J Surg Oncol. 2019;45(1):3–11. Scholar
  8. 8.
    Bosl J, Reaman G. Lack of guidelines, clinical data complicate treatment of rare cancers. HemOnc Today. 2008;9(11):9–13. Scholar
  9. 9.
    Dicato M. Cancer Research UK. What is a rare cancer? 2019;(2017):1–4.Google Scholar
  10. 10.
    Gatta G, Maarten Van Der Zwan J, Siesling S, Otter R, Tavilla A, Mallone S, et al. Surveillance of rare cancers in europe grant agreement no. 2006113 work package no. 5 deliverable no. 13 technical report with basic indicators for rare cancers and health care related macro indicators [Internet]. [cited 2018 Sep 30]. Available from:
  11. 11.
    RARECARENet. Data source and methods [Internet] [cited 2018 Oct 1]. Available from:
  12. 12.
    Reaman G. Lack of guidelines, clinical data complicate treatment of rare cancers. HemOnc Today. 2008;9(11):9–13.Google Scholar
  13. 13.
    Reaman G, Bosl J. Lack of guidelines, clinical data complicate treatment of rare cancers. HemOnc Today. 2008;9(11):9–13.Google Scholar
  14. 14.
    Gatta G, Van Der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011;47(17):2493–511.CrossRefGoogle Scholar
  15. 15.
    Gatta G, Trama A, Capocaccia R, RARECARENet Working Group. Epidemiology of rare cancers and inequalities in oncologic outcomes. Eur J Surg Oncol. 2019;45(1):3–11. Scholar
  16. 16.
    Chung C. Management of neuroendocrine tumors. Am J Heal Pharm. 2016;73(21):1719–44.CrossRefGoogle Scholar
  17. 17.
    Van Der Zwan JM, Trama A, Otter R, Larrañaga N, Tavilla A, Marcos-Gragera R, et al. Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. Eur J Cancer. 2013;49(11):2565–78.CrossRefGoogle Scholar
  18. 18.
    Tsoli M, Angelousi A, Rontogianni D, Stratakis C, Kaltsas G. Atypical manifestation of parathyroid carcinoma with late-onset distant metastases. Endocrinol Diab Metab Case Rep. 2017;Google Scholar
  19. 19.
    Cetani F, Pardi E, Marcocci C. Update on parathyroid carcinoma. J Endocrinol Investig [Internet]. 2016 [cited 2018 Oct 2];39:595–606. Available from: CrossRefGoogle Scholar
  20. 20.
    Komatsubara KM, Carvajal RD. The promise and challenges of rare cancer research. Lancet Oncol. 2016;17(2):136–8. Scholar
  21. 21.
    Simon Crompton. Ending the isolation. A guide to developing national rare cancer networks. Cancerworld J. 2017/2018;Winter:4–10.Google Scholar
  22. 22.
    Dixit N, Crawford GB, Lemonde M, Rittenberg CN, Fernández-Ortega P. Left behind: cancer disparities in the developed world. Support Care Cancer. 2016;24(8):3261–4. Scholar
  23. 23.
    ESMO Working Group. Improving rare cancer care in Europe recommendations on stakeholder actions and public policies [Internet]. European; [cited 2018 Oct 1]. Available from:
  24. 24.
    Mathoulin-Pélissier S, Pritchard-Jones K. Evidence-based data and rare cancers: the need for a new methodological approach in research and investigation. Eur J Surg Oncol. 2019;45(1):22–30.CrossRefGoogle Scholar
  25. 25.
    Blay JY, Coindre JM, Ducimetière F, Ray-Coquard I. The value of research collaborations and consortia in rare cancers. Lancet Oncol. 2016;17(2):e62–9.CrossRefGoogle Scholar
  26. 26.
    Billingham L, Malottki K, Steven N. Research methods to change clinical practice for patients with rare cancers. Lancet Oncol. 2016;17(2):e70–80. Scholar
  27. 27.
    Sharifnia T, Hong AL, Painter CA, Boehm JS. Emerging opportunities for target discovery in rare cancers. Cell Chem Biol. 2017 [cited 2018 Sep 29];24(9):1075–91. CrossRefGoogle Scholar
  28. 28.
    Boyd N, Dancey JE, Gilks CB, Huntsman DG. Rare cancers: a sea of opportunity. Lancet Oncol. 2016;17(2):e52–61. Scholar
  29. 29.
    Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, et al. Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative. Eur J Cancer. 2015;51(3):271–81.CrossRefGoogle Scholar
  30. 30.
    Foster J. Insider research with family members who have a member living with rare cancer. Int J Qual Methods. 2009;8 [cited 2018 Oct 2]. Available from: CrossRefGoogle Scholar
  31. 31.
    Sugawara Y, Narimatsu H, Hozawa A, Shao L, Otani K, Fukao A. Cancer patients on Twitter: a novel patient community on social media. BMC Res Notes [Internet]. 2012;5:699. Available from:
  32. 32.
    Webpage. Cancers rares Le Centre Léon Bérard pilote le Réseau Européen de référence. Le Centre Léon Bérard.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Nursing Research Institute Català d’OncologiaUniversity of BarcelonaBarcelonaSpain
  2. 2.Nuclear Medicine DepartmentHospital Universitary of BellvitgeBarcelonaSpain

Personalised recommendations